ישראל - עברית - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adult and paediatric patients of 4 years of age and over with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adult and paediatric patients with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

ישראל - עברית - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin

ישראל - עברית - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of four years onwards. boostrix polio is not intended for primary immunisation. the administration of boostrix polio should be based on official recommendations.

ישראל - עברית - Ministry of Health

inovamed ltd - rizatriptan as benzoate - טבליה - rizatriptan as benzoate 10 mg - rizatriptan

ישראל - עברית - Ministry of Health

inovamed ltd - rizatriptan as benzoate - טבליות מסיסות בפה - rizatriptan as benzoate 10 mg - rizatriptan

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - calcium carbonate - טבליות לעיסות - calcium carbonate 500 mg - calcium carbonate - calcium carbonate - antacid, calcium supplement.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - calcium as carbonate - טבליות לעיסות - calcium as carbonate 500 mg - calcium carbonate - calcium carbonate - antacid, calcium supplement.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative